XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue    
Revenue $ 500 $ 4,850
Cost of goods sold    
Cost of goods sold 213 2,304
Gross margin 287 2,546
Operating expenses:    
Research and development 6,818 4,634
General and administrative 1,314 1,465
Total operating expenses 8,132 6,099
Loss from operations (7,845) (3,553)
Other income (loss):    
Interest income 101 109
Other expense 0 (10)
Foreign exchange gain (loss) 1,290 409
Total other income 1,391 508
Loss before income taxes (6,454) (3,045)
Provision/(benefit) for income taxes (1,059) (477)
Net loss $ (5,395) $ (2,568)
Net loss per share—basic and diluted (in dollars per share) $ (0.18) $ (0.09)
Shares used to compute basic net loss per share (in shares) 30,043,380 29,423,727
Manufacturing Revenue [Member]    
Revenue    
Revenue $ 500 $ 4,500
Cost of goods sold    
Cost of goods sold 213 2,035
Clinical Trial Service Revenue [Member]    
Revenue    
Revenue 0 350
Cost of goods sold    
Cost of goods sold $ 0 $ 269